Skip to main content
MSF.org
  • English
  • العربية
  • Español
  • Français
Guides médicaux MSF
Guides médicaux MSF

Main navigation

  • Home
  • Guidelines
  • Updates
  • Order
  • About
  • Favorites
  • Contact

All guidelines

Tuberculosis

Essential drugs

Anglais العربية Espagnol Français

Clinical guidelines - Diagnosis and treatment manual

Anglais العربية Espagnol Français

Essential obstetric and newborn care

Anglais العربية Français

Management of A CHOLERA EPIDEMIC

Anglais Français

Management of A MEASLES EPIDEMIC

Anglais Français

Tuberculosis

Anglais Français

Public health engineering

Anglais Français
  • Authors/Contributors
  • Introduction
  • Abbreviations and acronyms
  • Chapter 1: Introduction and epidemiology
  • Chapter 2: Clinical presentation
  • Chapter 3: Diagnosis and follow-up investigations
  • Chapter 4: Diagnostic algorithms for pulmonary tuberculosis (PTB) in adults and adolescents
  • Chapter 5: Diagnosis of tuberculosis in children
  • Chapter 6: Intensive case finding in HIV-infected individuals
  • Chapter 7: Case definitions for registration
  • Chapter 8: Tuberculosis drugs and treatment regimens
  • Chapter 9: Treatment of drug-susceptible tuberculosis
  • Chapter 10: Treatment of multidrug-resistant TB (MDR-TB)
  • Chapter 11: Treatment of mono- and poly-drug resistant tuberculosis (PDR-TB)
  • Chapter 12: Co-management and treatment of HIV in TB disease
  • Chapter 13: Adherence to tuberculosis treatment
  • Chapter 14: Tuberculosis infection control
  • Chapter 15: Follow-up of staff exposed to tuberculosis
  • Chapter 16: Treatment of latent tuberculosis infection
  • Chapter 17: Monitoring and evaluation
  • Appendices
    • Appendix 1. Xpert assays
    • Appendix 2. Interpretation of Xpert assay results
    • Appendix 3. Sputum specimen: collection, storage and shipment
    • Appendix 4. Sputum smear microscopy
    • Appendix 5. Time required for diagnostic test results
    • Appendix 6. Ventilated work station (VWS) and bio-safety cabinet (BSC)
    • Appendix 7. Lymph node fine needle aspiration
    • Appendix 8. Protein estimation
    • Appendix 9. Tuberculin skin test
    • Appendix 10. Drug information sheets and patient instructions for the treatment of tuberculosis
      • Tuberculosis drug information sheets
      • Patient instructions
    • Appendix 11. Use of tuberculosis drugs in pregnant or breastfeeding women
    • Appendix 12. Dose adjustments in renal insufficiency
    • Appendix 13. Daily dose of tuberculosis drugs using fixed-dose combinations
    • Appendix 14. Monitoring of patients on drug-susceptible tuberculosis treatment
    • Appendix 15. Monitoring of patients on drug-resistant tuberculosis treatment
    • Appendix 16. Additional investigations in drug-resistant tuberculosis
    • Appendix 16. Basic TB infection control risk assessment tool
    • Appendix 17. Management of adverse effects
    • Appendix 17. Air change per hour (ACH) measurement recommendations
    • Appendix 18. Compassionate use
    • Appendix 18. Advantages and disadvantages of ventilation techniques
    • Appendix 19. Drug interactions and overlapping toxicities
    • Appendix 19. Upper room ultraviolet germicidal irradiation (UVGI) system
    • Appendix 20. Treatment supporters
    • Appendix 21. Informing the patient
    • Appendix 23. Treatment card for patients on first-line anti-TB therapy
    • Appendix 24. Tuberculosis register for patients on first-line anti-TB therapy
    • Appendix 25. Treatment card for patients on second-line anti-TB therapy
    • Appendix 26. Tuberculosis register for patients on second-line anti-TB therapy
    • Appendix 27. Respirators
    • Appendix 27. Request form for microscopy and Xpert MTB/RIF
    • Appendix 28. Surgical masks
    • Appendix 28. Request form for sputum culture, LPA and DST
    • Appendix 29. BCG vaccine
    • Appendix 29. Sputum smear microscopy register
    • Appendix 30. Xpert MTB/RIF register
    • Appendix 31. Drug-o-gram
    • Appendix 32. Quaterly report
    • Appendix 33. Report on detection and enrolment of TB cases with rifampicin and multidrug-resistance
    • Appendix 34. Report of final outcomes of drug-resistant tuberculosis
    • Appendix 35. Check-list for the evaluation of a TB service

Breadcrumb

  • Accueil
  • Tuberculosis
  • Appendices

Appendix 10. Drug information sheets and patient instructions for the treatment of tuberculosis

Select language:
Enter
Download
Comment
Return to top
On this page

     

     

    Update: November 2022

     

    • Tuberculosis drug information sheets
      • Amikacin (Am)
      • Amoxicillin/clavulanic acid ratio 4:1 (Amx/Clv)
      • Bedaquiline (Bdq)
      • Clofazimine (Cfz)
      • Cycloserine (Cs) or terizidone (Trd)
      • Delamanid (Dlm)
      • Ethambutol (E)
      • Ethionamide (Eto) or prothionamide (Pto)
      • Imipenem/cilastatin (Ipm/Cln)
      • Isoniazid - Standard dose (H)
      • Isoniazid - High dose (Hh)
      • Levofloxacin (Lfx)
      • Linezolid (Lzd)
      • Meropenem (Mpm)
      • Moxifloxacin (Mfx)
      • Para-aminosalicylate sodium (PAS)
      • Pretomanid (Pa)
      • Pyrazinamide (Z)
      • Rifabutin (Rfb)
      • Rifampicin (R)
      • Rifapentine (P)
      • Streptomycin (S)
    • Patient instructions
      • Patients on drug-susceptible TB treatment
      • Patients on drug-resistant TB treatment
    Path

    Book traversal links for Appendix 10. Drug information sheets and patient instructions for the treatment of tuberculosis

    • Appendix 9. Tuberculin skin test
    • Tuberculosis drug information sheets

    Commentaire sur cette page ou question générale

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
    Guides médicaux MSF
    Guides médicaux MSF
    © Médecins Sans Frontières 2023

    Footer

    • Disclaimer
    • Cookie Policy
    • Privacy Notice